ProfileGDS5678 / 1455185_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 52% 54% 52% 47% 51% 57% 51% 51% 49% 50% 59% 53% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.264651
GSM967853U87-EV human glioblastoma xenograft - Control 23.2454152
GSM967854U87-EV human glioblastoma xenograft - Control 33.3538454
GSM967855U87-EV human glioblastoma xenograft - Control 43.1920152
GSM967856U87-EV human glioblastoma xenograft - Control 53.0533647
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3178251
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5582257
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2260751
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2117451
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1403549
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1902450
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5034759
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2992153
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2641852